Study of ATH434 in Participants With Multiple System Atrophy

• Status: Not yet recruiting
• Trial end date: 2023-11-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will assess the safety and efficacy of ATH434 in participants with Multiple System Atrophy

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Alterity Therapeutics

Criteria

Inclusion Criteria:

1. Participant has clinical features of parkinsonism.

2. Participant has evidence of autonomic dysfunction.

3. Participant has at least one supportive clinical feature of MSA.

4. Participant is ambulatory.

Exclusion Criteria:

1. Participant has long duration of motor symptoms.

2. Participant has advanced disease.

3. Participant has structural brain abnormality on MRI.

4. Participant has any significant neurological disorder other than MSA.

5. Participant has an unstable medical or psychiatric illness.